辛复宁联合保妇康栓治疗宫颈高危型人乳头瘤病毒感染53例

Xinfuning Combined with Baofukang Suppository for 53 Cases with Cervical High-risk Human Papillomavirus Infection

[目的]探讨辛复宁(重组人干扰素α-2b阴道泡腾胶囊)联合保妇康栓治疗宫颈高危型人乳头瘤病毒(hr-HPV)感染的有效性。[方法]2009年9月至2010年12月,120例采用杂交捕获二代确定为宫颈高危型HPV感染患者随机分成3组:辛复宁组(n=35)、保妇康栓组(n=32)、两种药物联合组(n=53),观察治疗后HPV转阴情况。[结果]辛复宁组、保妇康栓组及联合组HPV转阴率分别为54.3%、59.4%和86.8%,以联合治疗组转阴率最高(χ2=12.96,P<0.05)。[结论]辛复宁与保妇康栓联合用药能有效治疗hr-HPV感染。

[Purpose] To investigate the effect of Xinfuning（recombinant human interferon α2b vaginal effervescent capsules） combined with Baofukang suppository in the treatment for cervical high-risk human papillomavirus（hr-HPV） infection.[Method] From September 2009 to December 2010,120 cases with cervical hr-HPV infection determined by hybrid capture Ⅱ technique were randomly divided into 3 groups： Xinfuning group,Baofukang suppository group and combination group.The HPV negative conversion rate after treatment was observed.[Results] The HPV negative conversion rate in Xinfuning group,Baofukang suppository group and combination group was 54.3%,59.4% and 86.8% respectively,the combination group presented the highest negative conversion rate（χ 2 =12.96,P0.05）.[Conclusion] Xinfuning combined with Baofukang suppository for patients with hr-HPV infection is effective.